Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

Phase 1
2(66.7%)
N/A
1(33.3%)
3Total
Phase 1(2)
N/A(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT07410403Enrolling By Invitation

AI-Based Fine Morphological Subtyping of Myeloma Single Cells for Predicting FISH Abnormalities

Role: lead

NCT06799676Phase 1Not Yet Recruiting

A Phase Ib/II Clinical Study on the Application of Linperlisib Combined with the VRD Regimen in Newly Diagnosed Patients with Multiple Myeloma

Role: lead

NCT05970198Not ApplicableRecruiting

Helical Tomotherapy in Multiple Myeloma

Role: lead

NCT04836871Phase 1Unknown

Double Filtration Plasmapheresis Combined With Chemotherapy

Role: lead

All 4 trials loaded